WNK2 and osteoporosis: There is also evidence that osteoclast-like cells (RAW264.7) treated with fucoxanthin inhibited markers of bone resorption and osteoclast differentiation by regulating the expression of some mitogen-activated protein kinases and nuclear factor erythroid 2-related factor 2 (NRF2), therefore providing a therapeutic benefit for osteoclast-related diseases such as osteoporosis [92].